Recent developments in molecular therapeutic approaches for rheumatoid arthritis

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 4, 2004, Pages 395-402

  Woods, Andrew ^a   Hobson, Philip ^a   Klavinskis, Linda S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokines; Gene therapy; Inflammation; Plasmid DNA; Rheumatoid arthritis; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CATALASE; COLLAGEN TYPE 2; CYTOKINE; ETANERCEPT; FAS LIGAND; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18 BINDING PROTEIN C; INTERLEUKIN 4; INTERLEUKIN 6; LENTIVIRUS VECTOR; METALLOPROTEINASE INHIBITOR; PEPTIDE; PLASMID DNA; PLASMID VECTOR; RAS PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 4; RETROVIRUS VECTOR; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VIRUS DNA; VIRUS RNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL TRANSFER; CLINICAL TRIAL; DENDRITIC CELL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG SAFETY; ENCEPHALITIS; GENE TARGETING; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANNUS; PROMOTER REGION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 4444370325     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Udalova IA, Richardson A, Ackerman H, Wordsworth P, Kwiatkowski D: Association of accelerated erosive rheumatoid arthritis with a polymorphism that alters NF-κB binding to the TNF promoter region. Rheumatology (2002) 41(7):830-831.
2. Waldron-Lynch F, Adams C, Amos C, Zhu DK, McDermott MF, Shanahan F, Molloy MG, O'Gara F: Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun (2001) 2(2):82-87.
3. Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, Nelissen RG, Westendorp RG, Hoeben RC, Breedveld FC, Toes RE, Huizinga TW: Association of the -2849 interieukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum (2003) 48(7):1841-1848.
4. Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, Pitzalis C, Drossaers-Bakker WK, Westendorp RG, Breedveld FC, Panay G, Verweij CL: Are differences in interleukin 10 production associated with joint damage? Rheumatology (2000) 39(11):1180-1188.
5. Field M: Tumour necrosis factor polymorphisms in rheumatic diseases. Q J Med (2001) 94(5):237-246.
6. Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, Boissier MC: Modulation of proinflammatory cytokine production in tumour necrosis factor-α (TNF-α)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol (1998) 111(2):391-396.
7. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD: Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol (2001) 166(5):3499-3505.
8. Murray KM, Dahl SL: Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother (1997) 31(11):1335-1338.
9. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum (2002) 46(10):2565-2570.
10. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA: Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol (2001) 137(7):893-899.
11. Spier RE: International meeting on the nucleic acid vaccines for the prevention of infectious disease and regulating nucleic acid (DNA) vaccines. Natcher Conference Center NIH, Bethesda, MD 5-8 February. Vaccine (1996) 14(13):1285-1288.
12. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Schock HB, Zhang H, Faris JE, Way PA et al: Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev Biol (2000) 104:33-43.
13. Klavinskis LS, Barnfield C, Gao L, Parker S: Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol (1999) 162(1):254-262.
14. Kim JM, Ho SH, Hahn W, Jeong JG, Park EJ, Lee HJ, Yu SS, Lee CS, Lee YW, Kim S: Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther (2003) 10(15):1216-1224.
15. Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G: Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther (2000) 7(24):2105-2112.
16. Li XW, Lee DK, Chan AS, Alpar HO: Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles. Biochim Biophys Acta (2003) 1630(1):7-18,
17. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH: CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther (2002) 5(6):731-738.
18. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 375(6530):411-415.
19. Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J et al: A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther (1999) 10(18):2973-2985.
20. D'Ambrosio E, Del Grosso N, Chicca A, Midulla M: Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg (1982) 89(1):155-161.
21. Flomenberg P, Piaskowski V, Truitt RL, Casper JT: Characterization of human proliferative T cell responses to adenovirus. J Infect Dis (1995) 171(5):1090-1096.
22. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW: Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors. Pediatrics (1998) 101(6):1013-1019.
23. Rosenecker J, Harms KH, Bertele RM, Pohl-Koppe A, Mutius E, Adam D, Nicolai T: Adenovirus infection in cystic fibrosis patients: Implications for the use of adenoviral vectors for gene transfer. Infection (1996) 24(1):5-8.
24. Croyle MA, Chirmule N, Zhang Y, Wilson JM: PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther (2002) 13(15):1887-1900.
25. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M et al: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol (2003) 77(15):8263-8271.
26. Sakhuja K, Reddy PS, Ganesh S, Cantaniag F, Pattison S, Limbach P, Kayda DB, Kadan MJ, Kaleko M, Connelly S: Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther (2003) 14(3):243-254.
27. Wang L, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, Kramer MG, Prieto J, Qian C: Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. Gastroenterology (2004) 126(1):278-289.
28. Zerby D, Sakhuja K, Reddy PS, Zimmerman H, Kayda D, Ganesh S, Pattison S, Brann T, Kadan MJ, Kaleko M, Connelly S: In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther (2003) 14(8):749-761.
29. Zou L, Zhou H, Pastore L, Yang K: Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther (2000) 2(2):105-113.
30. Ossevoort M, Visser BM, van den Wollenberg DJ, van der Voort EI, Offringa R, Melief CJ, Toes RE, Hoeben RC: Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther (2003) 10(24):2020-2028.
31. Zhang YC, Powers M, Wasserfall C, Brusko T, Song S, Flotte T, Snyder RO, Potter M, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM et al: Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Ther (2004) 11(3):233-240.
32. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther (1999) 6(9):1574-1583.
33. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, Robbins PD, Evans CH: Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol (1999) 162(6):3625-3632.
34. Saidenberg-Kermanac'h N, Bessis N, Deleuze V, Bloquel C, Bureau M, Scherman D, Boissier MC: Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med (2003) 5(2):164-171.
35. Miyata M, Sasajima T, Sato H, Saito A, Iriswa A, Sato Y, Kasukawa R: Suppression of collagen induced arthritis in mice utilizing plasmid DNA encoding interleukin 10. J Rheumatol (2000) 27(7):1601-1605.
36. Slavin AJ, Maron R, Weiner HL: Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol (2001) 13(6):825-833.
37. Lubberts E, Joosten LA, van Den Bersselaar L, Helsen MM, Bakker AC, van Meurs JB, Graham FL, Richards CD, van Den Berg WB: Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol (1999) 163(8):4546-4556.
38. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N: Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther (2000) 7(22):1930-1939.
39. Woods JM, Amin MA, Katschke KJ Jr, Volin MV, Ruth JH, Connors MA, Woodruff DC, Kurata H, Arai K, Haines GK 3rd, Kumar P, Koch AE: Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther (2002) 13(3):381-393.
40. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y: Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum (1999) 42(1):90-99.
41. Mi Z, Ghivizzani SC, Lechman E, Glorioso JC, Evans CH, Robbins PD: Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor β 1 into rabbit knees. Arthritis Res Ther (2003) 5(3):R132-R139.
42. Szekanecz Z, Koch AE, Kunkel SL, Strieter RM: Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention. Drugs Aging (1998) 12(5):377-390.
43. Tarner IH, Nakajima A, Seroogy CM, Ermann J, Levicnik A, Contag CH, Fathman CG: Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin Immunol (2002) 105(3):304-314.
44. Annenkov A, Chernajovsky Y: Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCRζ. Gene Ther (2000) 7(8 ):714-722.
45. Annenkov AE, Moyes SP, Eshhar Z, Mageed RA, Chernajovsky Y: Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc ERI-signaling γ subunit. J Immunol (1998) 161(12):6604-6613.
46. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z, Evans CH, Robbins PD: Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol (1999) 163(4):2202-2208.
47. Lechman ER, Keravala A, Nash J, Kim SH, Mi Z, Robbins PD: The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther (2003) 10(24):2029-2035.
48. Mukherjee P, Wu B, Mayton L, Kim SH, Robbins PD, Wooley PH: TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis (2003) 62(8):707-714.
49. Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM: Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther (2002) 6(6):727-736.
50. Smith R, Tarner IH, Hollenhorst M, Lin C, Levicnik AU, Fathman CG, Nolan GP: Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Gene Ther (2003) 10(15):1248-1257.
51. Oligino T, Ghivizzani S, Wolfe D, Lechman E, Krisky D, Mi Z, Evans C, Robbins P, Glorioso J: Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther (1999) 6(10):1713-1720.
52. Gouze E, Pawliuk R, Gouze JN, Pilapil C, Fleet C, Palmer GD, Evans CH, Leboulch P, Ghivizzani SC: Lentiviral-mediated gene delivery to synovium: Potent intra-articular expression with amplification by inflammation. Mol Ther (2003) 7(4):460-466.
53. Gouze E, Pawliuk R, Pilapil C, Gouze JN, Fleet C, Palmer GD, Evans CH, Leboulch P, Ghivizzani SC: In vivo gene delivery to synovium by lentiviral vectors. Mol Ther (2002) 5(4):397-404.
54. Dai L, Claxson A, Marklund SL, Feakins R, Yousaf N, Chernajovsky Y, Winyard PG: Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes. Gene Ther (2003) 10(7):550-558.
55. van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther (2003) 10(3):234-242.
56. Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther (2003) 10(12):1004-1011.
57. Quayle AJ, Chomarat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB: Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol (1993) 38(1):75-82.
58. Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG: Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest (2001) 107(10):1293-1301.
59. Zhang HG, Liu D, Heike Y, Yang P, Wang Z, Wang X, Curiel DT, Zhou T, Mountz JD: Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol (1998) 16(11):1045-1049.
60. Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, Mountz JD: CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest (2003) 112(9):1332-1341.
61. Yao Q, Wang S, Glorioso JC, Evans CH, Robbins PD, Ghivizzani SC, Oligino TJ: Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol Ther (2001) 3(6):901-910.
62. Yao Q, Glorioso JC, Evans CH, Robbins PD, Kovesdi I, Oligino TJ, Ghivizzani SC: Adenoviral mediated delivery of Fas ligand to arthritic joints causes extensive apoptosis in the synovial lining. J Gene Med (2000) 2(3):210-219.
63. Yao Q, Wang S, Gambotto A, Glorioso JC, Evans CH, Robbins PD, Ghivizzani SC, Oligino TJ: Intra-articular adenoviral-mediated gene transfer of TRAIL induces apoptosis of arthritic rabbit synovium. Gene Ther (2003) 10(12):1055-1060.
64. Yamamoto A, Fukuda A, Seto H, Miyazaki T, Kadono Y, Sawada Y, Nakamura I, Katagiri H, Asano T, Tanaka Y, Oda H et al: Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum (2003) 48(9):2682-2692.
65. Clavel G, Bessis N, Boissier MC: Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine (2003) 70(5):321-326.
66. Afuwape AO, Feldmann M, Paleolog EM: Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther (2003) 10(23):1950-1960.
67. Rygg M, Uhlar CM, Thorn C, Jensen LE, Gaughan DJ, Varley AW, Munford RS, Goke R, Chen Y, Whitehead AS: In vitro evaluation of an enhanced human serum amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy. Scand J Immunol (2001) 53(6):588-595.
68. Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C: Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: Application to experimental arthritis. Hum Gene Ther (2002) 13(10):1179-1188.
69. Ritter T, Brandt C, Prosch S, Vergopoulos A, Vogt K, Kolls J, Volk HD: Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine (2000) 12(8):1163-1170.
70. Evans CH, Robbins PD: The promise of a new clinical trial - intraarticular IL-1 receptor antagonist. Proc Assoc Am Physicians (1996) 108(1):1-5.
71. Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, Robbins PD: Clinical trials in the gene therapy of arthritis. Clin Orthop (2000) 379:S300-S307.
72. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L, Bratt J: Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis (2003) 62(6):526-529.
73. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position-308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum (2003) 48(7):1849-1852.
74. Neumann E, Judex M, Kullmann F, Grifka, J, Robbins PD, Pap T, Gay RE, Evans CH, Gay S, Scholmerich J, Muller-Ladner U: Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther (2002) 9(22):1508-1519.
75. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD: Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther (2002) 6(5):591-600.